Phase 2 BOLD Extension Study Efficacy Results for Siponimod (BAF312) in Patients With Relapsing–Remitting Multiple Sclerosis

O. Stuve, H. P. Hartung, M. Freedman, D. Li, B. Hemmer, L. Kappos , P. Rieckmann, X. Montalban, T. Ziemssen, K. Selmaj, USA, Germany, Switzerland, Spain